CROIX RESEARCH LIBRARY
What a COA Can and Cannot Tell You
Understanding Certificates of Analysis • Laboratory Verification • Research Quality & Transparency
A Certificate of Analysis (COA) is one of the most important documents used to evaluate the analytical characteristics of research peptides and related compounds.
However, a COA is often misunderstood.
A laboratory report showing 99% purity does not necessarily mean a vial contains the correct amount of peptide, is sterile, is free from endotoxins, or is safe for human administration.
Likewise, a passing laboratory report for one sample does not establish that every vial or batch of the same product has identical characteristics.
Understanding what a COA measures, what its results mean, and what it cannot establish is essential for responsible interpretation of research compound documentation.
At Croix, analytical transparency means presenting laboratory findings accurately, identifying the specific samples tested, and avoiding claims that extend beyond the available evidence.
RESEARCH EDUCATION • ANALYTICAL TRANSPARENCY • LOT SPECIFIC DOCUMENTATION
1. WHAT IS A CERTIFICATE OF ANALYSIS?
A Certificate of Analysis is a document that reports the results of laboratory testing performed on a specific sample or manufacturing lot.
Depending on the product, laboratory, and tests requested, a COA may include information about:
Chemical identity
Chromatographic purity
Active compound content
Impurities and degradation products
Sterility testing
Bacterial endotoxin levels
Physical or chemical characteristics
Not every COA includes all of these measurements.
Some reports contain only chemical identity and purity testing.
Others include additional analytical or microbiological testing.
The value of a COA depends on the quality of the testing, the methods used, the laboratory's competence, and whether the report can be traced to the product being evaluated.
IMPORTANT DISTINCTION
A COA is evidence about the sample tested. It is not a universal guarantee about every product carrying the same name.
2. WHAT A COA CAN TELL YOU
When supported by appropriate analytical methods, a COA can provide meaningful information about a research compound.
CHEMICAL IDENTITY
Identity testing evaluates whether the substance in a sample is consistent with the compound it is claimed to contain.
For peptides, laboratory methods may include:
Mass Spectrometry (MS)
Measures the mass-to-charge characteristics of ions and can help establish whether the molecular mass is consistent with the expected compound.
Liquid Chromatography–Mass Spectrometry (LC-MS)
Combines chemical separation with mass spectrometric analysis to support compound identification.
Tandem Mass Spectrometry (MS/MS)
May provide additional structural information through molecular fragmentation patterns.
These methods can help establish chemical identity, but the degree of certainty depends on the method and supporting data.
For example, a molecular mass match alone may not distinguish peptides with different amino acid sequences but identical molecular masses.
CHEMICAL PURITY
Purity testing evaluates the relative proportion of the intended compound compared with impurities detected by a particular analytical method.
High-performance liquid chromatography (HPLC) is commonly used for peptide purity analysis.
A chromatogram may show a principal peak corresponding to the intended compound and smaller peaks representing other detected components.
A report showing 99% HPLC purity can be useful evidence of chemical composition under the conditions of that test.
However, it does not necessarily establish that 99% of the total vial mass is active peptide.
ACTIVE COMPOUND CONTENT
Some laboratory reports include quantitative assay or content testing.
This evaluates how much of the intended compound is present.
For example, a vial labeled 10 mg may be tested to determine whether its actual peptide content is consistent with that label.
Content and purity are different measurements.
A product can have high chromatographic purity while containing less active compound than the labeled amount.
STERILITY TESTING
When included, sterility testing evaluates whether viable microorganisms are detected under specified laboratory conditions.
A report may reference USP <71> Sterility Tests.
A passing result provides information about the tested sample under the conditions of the method.
It does not establish with absolute certainty that every unit in a batch is sterile.
BACTERIAL ENDOTOXIN TESTING
Endotoxin testing measures bacterial endotoxins, which are associated with the outer membranes of Gram-negative bacteria.
A report may reference USP <85> Bacterial Endotoxins Test or an appropriate validated alternative.
Results may be expressed in Endotoxin Units, abbreviated EU.
These measurements are especially relevant when evaluating the microbiological quality of materials intended for sterile pharmaceutical applications.
A passing endotoxin test provides information about endotoxin levels in the tested sample.
It does not establish chemical identity, sterility, or overall clinical safety.
3. WHAT A COA CANNOT TELL YOU
A COA has important limitations, even when the laboratory results are favorable.
IT DOES NOT AUTOMATICALLY ESTABLISH SAFETY
A report showing high chemical purity does not establish that a compound is safe for human use.
Safety depends on factors including:
Pharmacology
Dose and exposure
Administration route
Toxicity
Immunogenicity
Drug interactions
Patient characteristics
Product formulation
Manufacturing quality
These factors generally require evidence beyond routine chemical testing.
IT DOES NOT ESTABLISH CLINICAL EFFECTIVENESS
A laboratory can verify that a sample contains a particular compound without establishing that the compound produces a therapeutic benefit.
Clinical effectiveness requires appropriate scientific investigation, including human studies when relevant.
A peptide may have excellent analytical results while having little or no convincing evidence of clinical benefit.
IT DOES NOT GUARANTEE STERILITY
Unless sterility testing was performed, a COA showing chemical identity and purity provides no direct evidence of sterility.
Even when sterility testing is included, the result must be interpreted within the limitations of the sampling procedure and test method.
IT DOES NOT GUARANTEE THE ABSENCE OF ENDOTOXINS
Sterility and endotoxin testing evaluate different hazards.
A sample may contain no detectable viable bacteria while still containing bacterial endotoxins.
Therefore, a passing sterility result does not replace endotoxin testing.
IT DOES NOT VERIFY UNTESTED LOTS
A COA for one lot cannot automatically be applied to another lot.
Differences in raw materials, manufacturing conditions, handling, storage, and degradation may affect product characteristics.
IT DOES NOT ESTABLISH FDA APPROVAL
A passing COA does not mean the FDA has approved the product.
FDA approval involves a separate regulatory process that evaluates evidence concerning safety, effectiveness, manufacturing quality, and other requirements.
IT DOES NOT ESTABLISH SUITABILITY FOR INJECTION
Even a report containing identity, purity, sterility, and endotoxin results does not by itself establish that a research compound is appropriate for human injection.
Additional pharmaceutical requirements may include validated manufacturing processes, formulation controls, container-closure integrity, stability testing, and other quality assessments.
Analytical quality and clinical suitability are separate questions.
4. WHY 99% PURITY DOES NOT MEAN 99% ACTIVE PEPTIDE
One of the most common misunderstandings involves the meaning of a high purity percentage.
UNDERSTANDING HPLC PURITY
In many peptide reports, HPLC purity is calculated from the relative areas of detected chromatographic peaks.
For example, a report may show:
Main Peak Area: 99.2%
This often indicates that the principal detected peak accounts for 99.2% of the integrated chromatographic signal under the specified analytical conditions.
It does not necessarily mean that 99.2% of the vial's total weight consists of the intended peptide.
Other components may include:
Water
Counterions
Residual solvents
Salts
Excipients
Substances not adequately detected by the method
EXAMPLE: PURITY VS. CONTENT
Consider a hypothetical vial labeled as containing 10 mg of peptide.
The laboratory reports:
HPLC Purity: 99.2%
Measured Peptide Content: 8.7 mg
These results are not inherently contradictory.
The peptide material may be highly pure while the actual amount present is below the labeled quantity.
The purity measurement describes relative chemical composition.
The content measurement describes the quantity of the intended compound.
IMPORTANT TAKEAWAY
Purity tells you about the composition measured by a method. Content tells you how much of the compound is present.
Both measurements can be valuable, but neither replaces the other.
5. WHY STERILITY AND ENDOTOXIN TESTING ARE DIFFERENT
Sterility and endotoxin testing are frequently grouped together, but they answer different questions.
STERILITY
Sterility testing investigates whether viable microorganisms are detected in a sample.
A result such as:
USP <71> — No Growth
indicates that no microbial growth was detected under the conditions of the test.
ENDOTOXINS
Endotoxin testing evaluates bacterial endotoxin contamination.
A report might provide a numerical result expressed in EU/mL, EU/mg, or EU/vial.
The applicable acceptance limit depends on the product and intended exposure.
WHY BOTH MATTER
Bacterial endotoxins can remain after bacteria are killed.
Therefore, a product can pass a sterility test while containing endotoxins.
Likewise, a product can have low endotoxin levels while containing other viable microorganisms.
REAL WORLD REGULATORY EXAMPLE
In 2019, the U.S. Food and Drug Administration reported adverse reactions associated with intravenous glutathione preparations made using ingredients with unsuitable endotoxin specifications.
This incident illustrates why chemical identity and purity alone are insufficient for evaluating the microbiological quality of injectable preparations.
IMPORTANT TAKEAWAY
Sterility testing evaluates viable microbial contamination. Endotoxin testing evaluates bacterial endotoxins. Neither test substitutes for the other.
6. HOW TO READ A PEPTIDE COA
A useful COA should provide enough information to understand what was tested and how the results relate to the product being evaluated.
LABORATORY NAME
The report should identify the laboratory responsible for testing.
Laboratory accreditation, method validation, and technical competence may be relevant when evaluating the reliability of results.
PRODUCT NAME
The compound identified on the report should match the product being represented.
Closely related peptide names should not automatically be treated as chemically identical.
PRODUCT STRENGTH
The report should identify the sample strength or content information when relevant.
For example:
BPC-157 — 10 mg
A report for one strength should not automatically be represented as verification of another.
LOT OR BATCH NUMBER
The lot or batch number connects the laboratory documentation to a specific production group.
This is a critical component of traceability.
SAMPLE ID
A unique sample identifier helps distinguish the tested material from other samples processed by the laboratory.
REPORT DATE
The report date establishes when the laboratory issued its findings.
ANALYTICAL METHODS
The COA should identify the methods used.
Examples include:
LC-MS for identity support
HPLC for chromatographic purity
Quantitative assay for active content
USP <71> for sterility testing
USP <85> for bacterial endotoxin testing
TEST RESULTS
The report should identify the actual findings.
Where appropriate, results should include numerical values, measurement units, and applicable acceptance criteria.
IMPORTANT DOCUMENTATION PRINCIPLE
A laboratory report should be interpreted according to the tests actually performed.
Missing test results should not be assumed to be favorable.
7. WHY LOT SPECIFIC DOCUMENTATION MATTERS
Laboratory results are tied to the samples tested.
Two products may share the same compound name and labeled strength while originating from different manufacturing batches.
Those batches may differ in:
Actual peptide content
Impurity profiles
Degradation products
Microbiological characteristics
Storage history
Manufacturing conditions
For this reason, a COA should not be treated as a universal certificate covering every product with the same name.
THE CROIX DOCUMENTATION STANDARD
Croix maintains available third party analytical documentation for specific samples and lots represented in its research library.
Before analytical documentation is presented as corresponding to a product, the following information must be matched:
Product name
Product strength
Lot or batch number
Sample ID
Testing laboratory
Report date
When a corresponding laboratory report cannot be established, Croix uses the following disclosure:
No matching Certificate of Analysis is currently displayed.
This avoids implying that an unrelated sample or batch has been verified.
IMPORTANT COA LIMITATION
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
8. CAN A COA BE AUTHENTIC BUT STILL MISLEADING?
Yes.
A COA can contain genuine laboratory results while being presented in a way that overstates what those results establish.
EXAMPLE 1: A PURITY REPORT PRESENTED AS COMPLETE QUALITY VERIFICATION
A laboratory tests a peptide using HPLC and reports 99% purity.
The result may be legitimate.
However, describing the product as fully tested for safety would be misleading if identity, content, sterility, endotoxins, and other relevant characteristics were not evaluated.
EXAMPLE 2: A COA FROM A DIFFERENT LOT
A supplier displays a legitimate COA for a previously tested lot.
The current product comes from a different batch.
The report does not establish the characteristics of the newer batch.
EXAMPLE 3: A RELATED BUT DIFFERENT PEPTIDE
A laboratory report identifies one peptide, while the product description uses the name of a related peptide fragment.
Even if the laboratory report is authentic, the identity discrepancy must be resolved before claiming that the report verifies the labeled compound.
EXAMPLE 4: A PASSING STERILITY RESULT WITHOUT ENDOTOXIN TESTING
A report shows no microbial growth.
That result does not establish acceptable endotoxin levels.
EXAMPLE 5: A REPORT WITHOUT TRACEABILITY
A laboratory report contains favorable results but lacks sufficient information to connect it to a specific product lot.
The findings may still describe the tested sample accurately, but their relevance to a particular vial remains unverified.
IMPORTANT TAKEAWAY
A COA should be evaluated not only for the results it contains, but also for the claims being made from those results.
9. DOES THIRD PARTY TESTING MAKE A PRODUCT SAFE?
Independent laboratory testing can provide valuable information.
It may reduce uncertainty about specific analytical characteristics when appropriate methods and representative samples are used.
However, independent testing does not eliminate every possible risk.
WHAT THIRD PARTY TESTING CAN SUPPORT
Appropriate testing may support statements concerning:
Chemical identity
Chromatographic purity
Measured content
Specified impurity levels
Sterility test results
Bacterial endotoxin measurements
These findings should be presented with their corresponding methods, sample identifiers, and limitations.
WHAT IT CANNOT REPLACE
Third party analytical testing does not replace:
Clinical trials
Toxicology studies
Drug interaction research
Validated pharmaceutical manufacturing
Stability studies
Regulatory approval
Appropriate medical oversight
A research compound may meet particular analytical specifications while remaining investigational or unsupported for human use.
IMPORTANT DISTINCTION
Verified chemical characteristics do not establish verified clinical benefits.
10. WHAT SHOULD YOU LOOK FOR BEFORE TRUSTING A COA?
When evaluating analytical documentation, the most useful questions are:
1. Is the laboratory clearly identified?
The report should identify who performed the testing.
2. Does the compound name match?
The tested substance should correspond to the product being represented.
3. Does the labeled strength match?
The sample and product should be traceable to the same formulation or strength.
4. Is there a matching lot or batch number?
A report for another batch should not be treated as direct verification.
5. Is the sample ID documented?
Unique identifiers improve traceability.
6. Are the testing methods identified?
Different analytical methods establish different characteristics.
7. Are the results clearly reported?
Numerical results, units, and acceptance criteria improve interpretation.
8. Were sterility and endotoxins actually tested?
Do not assume these tests were performed because purity testing was completed.
9. Are there any discrepancies?
Differences in compound names, strengths, sample identifiers, or laboratory descriptions should be investigated.
10. Are the claims limited to what was tested?
A trustworthy presentation should avoid extending sample-specific findings into unsupported claims about safety, effectiveness, or unrelated products.
11. HOW CROIX APPROACHES ANALYTICAL TRANSPARENCY
Croix's research documentation standard emphasizes accurate representation of available laboratory findings.
Analytical documentation is presented only when it can be matched to the corresponding sample or lot.
When documentation is available, the reported findings should be presented according to the laboratory's original report.
When documentation is unavailable or cannot be matched, that limitation should be disclosed.
LOT SPECIFIC REPORTING
Croix identifies relevant analytical information when available, including:
Product and strength
Lot or batch
Sample ID
Laboratory
Report date
Testing methods
Reported results
DOCUMENTATION LIMITATIONS
A laboratory report is not presented as proof of characteristics that were not tested.
A report for one sample is not presented as verification of another.
A passing COA is not presented as FDA approval or proof of clinical effectiveness.
WHY THIS MATTERS
Responsible research communication requires distinguishing what is known from what remains uncertain.
Analytical transparency is most useful when laboratory results are presented accurately and without exaggeration.
SELECTED RESEARCH & REGULATORY REFERENCES
United States Pharmacopeia
USP General Chapter <71> — Sterility Tests.
Compendial reference addressing sterility testing methods and interpretation.
United States Pharmacopeia
USP General Chapter <85> — Bacterial Endotoxins Test.
Compendial reference addressing bacterial endotoxin testing.
United States Pharmacopeia
USP General Chapter <621> — Chromatography.
General reference for chromatographic analytical techniques.
U.S. Food & Drug Administration
Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice.
Regulatory guidance addressing sterile pharmaceutical manufacturing and quality controls.
U.S. Food & Drug Administration
Pyrogen and Endotoxins Testing: Questions and Answers.
Regulatory guidance addressing bacterial endotoxin testing and applicable acceptance considerations.
U.S. Food & Drug Administration
FDA Highlights Concerns with Using Dietary Ingredient Glutathione to Compound Sterile Injectables. 2019.
FDA safety communication documenting concerns involving injectable glutathione and endotoxin-related adverse reactions.
U.S. Food & Drug Administration
21 CFR Parts 210 and 211.
Current Good Manufacturing Practice regulations addressing pharmaceutical manufacturing and quality systems.
RESEARCH & EDUCATIONAL INFORMATION
This article is provided for scientific and educational reference.
A Certificate of Analysis can provide valuable information about the analytical characteristics of a specific research compound sample.
However, a COA does not automatically establish safety, effectiveness, regulatory approval, sterility, or suitability for human administration.
The meaning of each laboratory result depends on the test performed, the analytical method, the sample examined, and the limitations of the testing process.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
A COA is an important piece of analytical evidence. Understanding its limitations is just as important as understanding its results.